Anti-angiogenic peptides for cancer therapeutics

Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan Pandey, Amir P. Tamiz, Aleksander S Popel

Research output: Contribution to journalArticle

Abstract

Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical andclinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascadeproteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinicalmodels of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g.,through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery andoptimization including computational and bioinformatics tools and novel experimental techniques.

Original languageEnglish (US)
Pages (from-to)1101-1116
Number of pages16
JournalCurrent Pharmaceutical Biotechnology
Volume12
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Angiogenic Proteins
Peptides
Thrombospondins
Neoplasms
Endostatins
Therapeutics
Proteins
Amino Acid Substitution
Microvessels
Computational Biology
Chemokines
Intercellular Signaling Peptides and Proteins
Collagen
Clinical Trials
Amino Acids

Keywords

  • Angiogenesis
  • Animal model
  • Computational biology
  • In vitro model
  • Inhibitor
  • Peptidomimetics
  • Tumor
  • Tumor vasculature

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Biotechnology

Cite this

Anti-angiogenic peptides for cancer therapeutics. / Rosca, Elena V.; Koskimaki, Jacob E.; Rivera, Corban G.; Pandey, Niranjan; Tamiz, Amir P.; Popel, Aleksander S.

In: Current Pharmaceutical Biotechnology, Vol. 12, No. 8, 08.2011, p. 1101-1116.

Research output: Contribution to journalArticle

Rosca, Elena V. ; Koskimaki, Jacob E. ; Rivera, Corban G. ; Pandey, Niranjan ; Tamiz, Amir P. ; Popel, Aleksander S. / Anti-angiogenic peptides for cancer therapeutics. In: Current Pharmaceutical Biotechnology. 2011 ; Vol. 12, No. 8. pp. 1101-1116.
@article{dfa4c485a9dc40efa33ff55576e6d2ef,
title = "Anti-angiogenic peptides for cancer therapeutics",
abstract = "Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical andclinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascadeproteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinicalmodels of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g.,through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery andoptimization including computational and bioinformatics tools and novel experimental techniques.",
keywords = "Angiogenesis, Animal model, Computational biology, In vitro model, Inhibitor, Peptidomimetics, Tumor, Tumor vasculature",
author = "Rosca, {Elena V.} and Koskimaki, {Jacob E.} and Rivera, {Corban G.} and Niranjan Pandey and Tamiz, {Amir P.} and Popel, {Aleksander S}",
year = "2011",
month = "8",
doi = "10.2174/138920111796117300",
language = "English (US)",
volume = "12",
pages = "1101--1116",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Anti-angiogenic peptides for cancer therapeutics

AU - Rosca, Elena V.

AU - Koskimaki, Jacob E.

AU - Rivera, Corban G.

AU - Pandey, Niranjan

AU - Tamiz, Amir P.

AU - Popel, Aleksander S

PY - 2011/8

Y1 - 2011/8

N2 - Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical andclinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascadeproteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinicalmodels of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g.,through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery andoptimization including computational and bioinformatics tools and novel experimental techniques.

AB - Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical andclinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascadeproteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinicalmodels of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g.,through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery andoptimization including computational and bioinformatics tools and novel experimental techniques.

KW - Angiogenesis

KW - Animal model

KW - Computational biology

KW - In vitro model

KW - Inhibitor

KW - Peptidomimetics

KW - Tumor

KW - Tumor vasculature

UR - http://www.scopus.com/inward/record.url?scp=79960006764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960006764&partnerID=8YFLogxK

U2 - 10.2174/138920111796117300

DO - 10.2174/138920111796117300

M3 - Article

VL - 12

SP - 1101

EP - 1116

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 8

ER -